Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years

Trial Profile

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Registrational
  • Acronyms RAMSES
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to an Aimmune Therapeutics media release, this trial is expected to support regulatory filings in the USA in late 2018.
    • 02 May 2017 Status changed from not yet recruiting to recruiting.
    • 23 Apr 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top